Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-Flu: DAS181 for Severe Influenza and COVID-19
NCT04298060Phase 2Unknown
- Sponsor
- Ansun Biopharma
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of DAS181 in influenza, coronavirus disease 2019 (COVID-19), parainfluenza virus infection, human metapneumovirus infection (HMPV), enterovirus infection, sponsored by Ansun Biopharma. Status: unknown.
02
Drugs
DAS181
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)parainfluenza virus infectionhuman metapneumovirus infection (HMPV)enterovirus infection
Beyond the preview
Go deeper on NCT04298060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298060.